Your session is about to expire
← Back to Search
Tyrosine Kinase Inhibitor
Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung Disease: a Pilot Study
N/A
Waitlist Available
Led By Deborah Assayag, MD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
This trial is testing a drug called nintedanib to see if it can safely help patients with lung scarring due to myositis-associated interstitial lung disease (MA-ILD) who are also taking immune-suppressing medications.
Eligible Conditions
- Myositis
- Interstitial Lung Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and adverse events
Tolerability - completed doses
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Nintedanib treatmentExperimental Treatment1 Intervention
Single arm treatment with nintedanib
Find a Location
Who is running the clinical trial?
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
471 Previous Clinical Trials
166,932 Total Patients Enrolled
Deborah Assayag, MDPrincipal InvestigatorResearch Institute - McGill University Health Center